John C.M. Farquhar serves as President and Chief Executive Officer of HeartFlow, Inc., a pioneering medical technology company transforming the diagnosis and management of coronary artery disease through its AI-powered, non-invasive HeartFlow Analysis platform. With more than 25 years of leadership in the medical device industry, Farquhar brings extensive expertise in cardiovascular innovation, commercial strategy, and global market expansion. His career began at Boston Scientific Corporation, where he advanced through sales, marketing, and general management roles, establishing a strong foundation in interventional cardiology and structural heart therapies. Prior to joining HeartFlow in 2021, Farquhar held the position of President of the Transcatheter Heart Valve franchise at Edwards Lifesciences, managing a multi-billion-dollar portfolio that delivered groundbreaking therapies for aortic stenosis and other valvular diseases. Under his stewardship, the business achieved record growth, secured pivotal regulatory approvals, and expanded access to life-saving treatments for millions of patients worldwide. His track record includes driving over $5 billion in annual revenue and fostering cross-functional teams to accelerate product development and clinical adoption. At HeartFlow, Farquhar has propelled the company to new heights, overseeing U.S. and European regulatory clearances for expanded indications of the HeartFlow platform, forging key partnerships with health systems and payers, and scaling operations to serve over 1,000 sites globally. His strategic vision emphasizes precision medicine to reduce unnecessary invasive procedures, improve patient outcomes, and lower healthcare costs, solidifying HeartFlow's role as a leader in preventive cardiac care.